Literature DB >> 23468483

Conformational epitope consisting of the V3 and V4 loops as a target for potent and broad neutralization of simian immunodeficiency viruses.

Takeo Kuwata1, Kaori Takaki, Kazuhisa Yoshimura, Ikumi Enomoto, Fan Wu, Ilnour Ourmanov, Vanessa M Hirsch, Masaru Yokoyama, Hironori Sato, Shuzo Matsushita.   

Abstract

Inducing neutralizing antibodies (NAb) is the key to developing a protective vaccine against human immunodeficiency virus type 1 (HIV-1). To clarify the neutralization mechanism of simian immunodeficiency virus (SIV), we analyzed NAb B404, which showed potent and broad neutralizing activity against various SIV strains. In 4 SIVsmH635FC-infected macaques, B404-like antibodies using the specific VH3 gene with a long complementarity-determining region 3 loop and λ light chain were the major NAbs in terms of the number and neutralizing potency. This biased NAb induction was observed in all 4 SIVsmH635FC-infected macaques but not in 2 macaques infected with a SIV mix, suggesting that induction of B404-like NAbs depended on the inoculated virus. Analysis using Env mutants revealed that the V3 and V4 loops were critical for B404 binding. The reactivity to the B404 epitope on trimeric, but not monomeric, Env was enhanced by CD4 ligation. The B404-resistant variant, which was induced by passages with increasing concentrations of B404, accumulated amino acid substitutions in the C2 region of gp120. Molecular dynamics simulations of the gp120 outer domains indicated that the C2 mutations could effectively alter the structural dynamics of the V3/V4 loops and their neighboring regions. These results suggest that a conformational epitope consisting of the V3 and V4 loops is the target for potent and broad neutralization of SIV. Identifying the new neutralizing epitope, as well as specifying the VH3 gene used for epitope recognition, will help to develop HIV-1 vaccines.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23468483      PMCID: PMC3648159          DOI: 10.1128/JVI.00201-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  79 in total

Review 1.  The design and evaluation of HIV-1 vaccines.

Authors:  Kevin O Saunders; Rebecca S Rudicell; Gary J Nabel
Journal:  AIDS       Date:  2012-06-19       Impact factor: 4.177

2.  Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Authors:  Aran F Labrijn; Pascal Poignard; Aarti Raja; Michael B Zwick; Karla Delgado; Michael Franti; James Binley; Veronique Vivona; Christoph Grundner; Chih-Chin Huang; Miro Venturi; Christos J Petropoulos; Terri Wrin; Dimiter S Dimitrov; James Robinson; Peter D Kwong; Richard T Wyatt; Joseph Sodroski; Dennis R Burton
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

3.  Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.

Authors:  Miroslaw K Gorny; Xiao-Hong Wang; Constance Williams; Barbara Volsky; Kathy Revesz; Bradley Witover; Sherri Burda; Mateusz Urbanski; Phillipe Nyambi; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner; Arthur Nadas
Journal:  Mol Immunol       Date:  2008-10-25       Impact factor: 4.407

4.  Complex determinants of macrophage tropism in env of simian immunodeficiency virus.

Authors:  K Mori; D J Ringler; T Kodama; R C Desrosiers
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

5.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Authors:  Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Michael S Seaman; Klara Velinzon; John Pietzsch; Rene G Ott; Robert M Anthony; Henry Zebroski; Arlene Hurley; Adhuna Phogat; Bimal Chakrabarti; Yuxing Li; Mark Connors; Florencia Pereyra; Bruce D Walker; Hedda Wardemann; David Ho; Richard T Wyatt; John R Mascola; Jeffrey V Ravetch; Michel C Nussenzweig
Journal:  Nature       Date:  2009-03-15       Impact factor: 49.962

6.  Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.

Authors:  Willy M J M Bogers; David Davis; Ilona Baak; Elaine Kan; Sam Hofman; Yide Sun; Daniella Mortier; Ying Lian; Herman Oostermeijer; Zahra Fagrouch; Rob Dubbes; Martin van der Maas; Petra Mooij; Gerrit Koopman; Ernst Verschoor; Johannes P M Langedijk; Jun Zhao; Egidio Brocca-Cofano; Marjorie Robert-Guroff; Indresh Srivastava; Susan Barnett; Jonathan L Heeney
Journal:  Virology       Date:  2008-10-22       Impact factor: 3.616

7.  Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain.

Authors:  Piraporn Utachee; Shota Nakamura; Panasda Isarangkura-Na-Ayuthaya; Kenzo Tokunaga; Pathom Sawanpanyalert; Kazuyoshi Ikuta; Wattana Auwanit; Masanori Kameoka
Journal:  J Virol       Date:  2010-02-17       Impact factor: 5.103

Review 8.  HIV vaccines.

Authors:  Andrew J McMichael
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

9.  Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens.

Authors:  Xiaodong Xiao; Weizao Chen; Yang Feng; Zhongyu Zhu; Ponraj Prabakaran; Yanping Wang; Mei-Yun Zhang; Nancy S Longo; Dimiter S Dimitrov
Journal:  Biochem Biophys Res Commun       Date:  2009-09-11       Impact factor: 3.575

10.  The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

Authors:  Rafick-Pierre Sekaly
Journal:  J Exp Med       Date:  2008-01-14       Impact factor: 14.307

View more
  17 in total

1.  Adaptation of an R5 Simian-Human Immunodeficiency Virus Encoding an HIV Clade A Envelope with or without Ablation of Adaptive Host Immunity: Differential Selection of Viral Mutants.

Authors:  Mingkui Zhou; Michael Humbert; Muhammad M Mukhtar; Hanna B Scinto; Hemant K Vyas; Samir K Lakhashe; Siddappa N Byrareddy; Gregor Maurer; Swati Thorat; Joshua Owuor; Zhao Lai; Yidong Chen; Anthony Griffiths; Agnès-Laurence Chenine; Sanjeev Gumber; François Villinger; David Montefiori; Ruth M Ruprecht
Journal:  J Virol       Date:  2019-04-17       Impact factor: 5.103

2.  Immunoglobulin VH gene diversity and somatic hypermutation during SIV infection of rhesus macaques.

Authors:  Kejun Guo; Kalani Halemano; Kimberly Schmitt; Miki Katuwal; Yaqiong Wang; Michael S Harper; Karl J Heilman; Takeo Kuwata; Edward B Stephens; Mario L Santiago
Journal:  Immunogenetics       Date:  2015-05-21       Impact factor: 2.846

3.  A Potent anti-Simian Immunodeficiency Virus Neutralizing Antibody Induction Associated with a Germline Immunoglobulin Gene Polymorphism in Rhesus Macaques.

Authors:  Saori Matsuoka; Takeo Kuwata; Hiroshi Ishii; Tsuyoshi Sekizuka; Makoto Kuroda; Masato Sano; Midori Okazaki; Hiroyuki Yamamoto; Mikiko Shimizu; Shuzo Matsushita; Yohei Seki; Akatsuki Saito; Hiromi Sakawaki; Vanessa M Hirsch; Tomoyuki Miura; Hirofumi Akari; Tetsuro Matano
Journal:  J Virol       Date:  2021-01-13       Impact factor: 5.103

4.  The value of HIV protective epitope research for informed vaccine design against diverse viral pathogens.

Authors:  Victor G Kramer; Siddappa N Byrareddy
Journal:  Expert Rev Vaccines       Date:  2014-06-26       Impact factor: 5.217

5.  High-Resolution Sequencing of Viral Populations during Early Simian Immunodeficiency Virus Infection Reveals Evolutionary Strategies for Rapid Escape from Emerging Env-Specific Antibody Responses.

Authors:  Sergio Ita; Alison K Hill; Evan C Lam; Fay J Dufort; Xiao Yang; Ruchi Newman; Sivan Leviyang; Ismael B Fofana; Welkin E Johnson
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

6.  Arginine insertion and loss of N-linked glycosylation site in HIV-1 envelope V3 region confer CXCR4-tropism.

Authors:  Kiyoto Tsuchiya; Hirotaka Ode; Tsunefusa Hayashida; Junko Kakizawa; Hironori Sato; Shinichi Oka; Hiroyuki Gatanaga
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

7.  Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein.

Authors:  Mark D Hicar; Xuemin Chen; Chidananda Sulli; Trevor Barnes; Jason Goodman; Hakimuddin Sojar; Bryan Briney; Jordan Willis; Valentine U Chukwuma; Spyros A Kalams; Benjamin J Doranz; Paul Spearman; James E Crowe
Journal:  PLoS One       Date:  2016-07-13       Impact factor: 3.240

8.  In silico Analysis of HIV-1 Env-gp120 Reveals Structural Bases for Viral Adaptation in Growth-Restrictive Cells.

Authors:  Masaru Yokoyama; Masako Nomaguchi; Naoya Doi; Tadahito Kanda; Akio Adachi; Hironori Sato
Journal:  Front Microbiol       Date:  2016-02-09       Impact factor: 5.640

9.  Neutralizing Antibody Induction Associated with a Germline Immunoglobulin Gene Polymorphism in Neutralization-Resistant SIVsmE543-3 Infection.

Authors:  Yuto Nomura; Saori Matsuoka; Midori Okazaki; Takeo Kuwata; Tetsuro Matano; Hiroshi Ishii
Journal:  Viruses       Date:  2021-06-21       Impact factor: 5.048

10.  Increased infectivity in human cells and resistance to antibody-mediated neutralization by truncation of the SIV gp41 cytoplasmic tail.

Authors:  Takeo Kuwata; Takaki Kaori; Ikumi Enomoto; Kazuhisa Yoshimura; Shuzo Matsushita
Journal:  Front Microbiol       Date:  2013-05-14       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.